Among US adolescents and young adults, HbA1c levels, central obesity, and smoking were associated with an increased risk of dying before 55 years of age.
Among US adolescents and young adults, hig h HbA1c levels, central obesity, and smoking were associated with an increased risk of dying before 55 years of age, according a study published recently in Pediatrics.
“We looked at risk factors for dying before the age of 55 years among adolescents and young adults in the United States,” lead author Sharon Saydah, PhD, CDR USPHS, Centers for Disease Control and Prevention, Division of Diabetes Translation, told Formulary.
“We found that after adjusting for age, sex, race/ethnicity; smoking status, measure of obesity, and glucose levels were associated with increased risk of early deaths. We found no association with cholesterol measures and early deaths,” Saydah said.
The researchers used data from CDC’s National Health and Nutrition Examination Survey (NHANES), 1988-1994, of participants aged 12 to 39 years with follow-up data on mortality status through 2006.
“We looked at the association of a number of risk factors included three measures of adiposity, glycated hemoglobin [HbA1c level, cholesterol levels, blood pressure, self-reported smoking status and cotinine level with death prior to age 55,” she said.
While previous studies have found risk factors such as obesity, cholesterol, glucose, smoking to increase the risk of disease among the younger adult population, few had looked at the association with early mortality, according to Saydah.
“These associations indicate a need for more effective community and clinical strategies for reducing the prevalence of these risk factors among US residents in these age groups,” she said. “The CDC has a number of resources and programs to address reducing these risk factors in the population including smoking cessation, type 2 diabetes prevention, and obesity reduction.” â
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More